Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology

The competitive bidding process for Medivation shows just how much big pharma is willing to pay for commercial-stage oncology assets. Now that Pfizer has won the biotech, it will have to prove Xtandi is worth the price.